SCHEDULE: Hyperscale Data Reports 9.99% Stake in DataMeds AI

Hyperscale Data, Inc. has disclosed a beneficial ownership of 9.99% in DataMeds AI, Inc. through convertible notes and warrants, with specific blockers in place.

Summary

• Hyperscale Data, Inc. has filed a Schedule 13G, indicating it beneficially owns 501,204 shares of DataMeds AI, Inc. common stock.
• This ownership represents 9.99% of the class of securities.
• The shares are issuable upon conversion of a convertible promissory note held by Ault Lending, LLC, a subsidiary of Hyperscale Data, Inc.
• The filing notes that an additional 123,796 shares are blocked due to a 9.99% beneficial ownership limit, and 245,419 shares from warrants are blocked by a 4.99% limit.
• The conversion of the note is assumed at an initial floor price of $1.00 per share for reporting purposes.
• The filing is based on 4,515,862 shares of DataMeds AI, Inc. common stock issued and outstanding as of August 18, 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing, primarily due to the disclosure of significant beneficial ownership which can sometimes precede further corporate actions or signal potential dilution concerns for existing shareholders.

Positives

• Hyperscale Data, Inc. has established a significant beneficial ownership stake in DataMeds AI, Inc., signaling strategic interest.
• The ownership is structured through convertible notes and warrants, which can offer flexibility and potential upside.

Negatives

• The disclosure of a 9.99% beneficial ownership, especially with conversion and exercise blockers, may indicate potential future dilution or strategic maneuvers that could impact existing shareholders.
• The reliance on a convertible note and warrants suggests that the actual ownership is not yet fully realized and is contingent on conversion and exercise terms.

Risks

• Potential for future dilution if the convertible note is converted and warrants are exercised, especially if the beneficial ownership blockers are removed or adjusted.
• The value of the investment is tied to the performance and stock price of DataMeds AI, Inc.
• The filing does not detail the specific terms or maturity of the convertible note or warrants beyond the conversion price assumption.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from DataMeds AI, Inc. It primarily reports on the current beneficial ownership status of Hyperscale Data, Inc.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that the disclosure of significant beneficial ownership via convertible instruments is a common strategy in the venture capital and early-stage investment landscape, often used to gain exposure to potential growth companies while managing immediate ownership thresholds.

Related Party Transactions

• Ault Lending, LLC, a wholly owned subsidiary of Ault Capital Group, Inc., which is a wholly owned subsidiary of Hyperscale Data, Inc., holds the convertible promissory note.

Stakeholder Impact

• Shareholders of DataMeds AI, Inc. should monitor potential future dilution if the convertible note is converted and warrants are exercised.
• Investors in Hyperscale Data, Inc. may see this as a strategic investment, but the ultimate value depends on DataMeds AI, Inc.'s performance.

Next Steps

• Hyperscale Data, Inc. may continue to hold or adjust its position in DataMeds AI, Inc.
• DataMeds AI, Inc. may issue further disclosures related to its outstanding securities or corporate actions.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, Convertible Note, Warrants, Hyperscale Data, DataMeds AI, Investment